Argenx stock: Robert W. Baird raises target to USD 861 for Argenx stock

Published on 10/23/2026 at 15:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue reached USD 1.75 billion on October 23, 2026. Argenx stock costs EUR 784.50 on October 23, 2026 at 3:35 p.m. CEST.

Analyst target and quarterly earnings

On October 23, 2026, Robert W. Baird lifted its target from USD 823.00 to USD 861.00.
Third-quarter 2026 earnings per share reached USD 7.80 versus USD 7.44 expected.
Argenx stock costs EUR 784.50 at Lang & Schwarz on October 23, 2026 at 3:35 p.m. CEST.

Isometrische 3D-Illustration eines Biotech-Campus, Schnittgebäude zeigen Labore mit Wissenschaftlern und schwebenden Proteinmodellen, Pastellblau-Grün-Weiß-Palette — Argenx NL0010832176 isometrische 3D-Ansicht eines modernen Biotech-Forschungscampus mit Schnittlaboren und schwebenden Proteinmodellen, Illustration mit AI erstellt.

Argenx (ISIN NL0010832176) is the subject of a new Robert W. Baird target revision, with the brokerage raising its price target from USD 823.00 to USD 861.00 on October 23, 2026, according to MarketBeat. The report retained a Neutral rating. Argenx stock was at EUR 784.50 at Lang & Schwarz on October 23, 2026 at 3:35 p.m. CEST.

Baird raises target to USD 861

The revised target remains below the Nasdaq quotation of USD 879.09 at 9:43 a.m. ET on October 23, 2026. Argenx's market capitalization stood at USD 55.3 billion, while the stock's 52-week range was USD 661.85 to USD 1,072.75.

Third-quarter earnings beat estimates

Argenx reported third-quarter 2026 revenue of USD 1.75 billion and diluted earnings per share of USD 7.80, according to MarketBeat. Earnings per share exceeded the USD 7.44 consensus estimate by USD 0.36, or 4.84 percent, for the period ended September 30, 2026.

Valuation keeps the range wide

The Nasdaq quotation carried a price-to-earnings ratio of 33.79 on October 23, 2026. The 52-week high of USD 1,072.75 was 18.07 percent above the Nasdaq price of USD 879.09, leaving the stock below its yearly peak despite the latest earnings beat.

How does Argenx compare?

Biogen traded at USD 248.24 on the Nasdaq at 9:44 a.m. ET on October 23, 2026, with a market capitalization of USD 36.7 billion and a price-to-earnings ratio of 43.96. UCB traded at EUR 264.20 on Euronext Brussels at 3:29 p.m. CEST, with a market capitalization of EUR 50.4 billion and a price-to-earnings ratio of 22.94.

Argenx stock stays below its yearly high

For investors, the latest picture combines a higher Baird target with a valuation that still sits below the 52-week high. The quarterly comparison also provides a concrete operating counterweight, with USD 7.80 in earnings per share against USD 7.44 expected.

Argenx was trading at EUR 784.50 at Lang & Schwarz on October 23, 2026 at 3:35 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Argenx stock.